The FDA has granted priority review for Bayer's new drug application for its non-steroidal mineralocorticoid receptor inhibitor antagonist finerenone for treating diabetic kidney disease. The decision was based on the findings from the FIDELIO-DKD study that found finerenone effectively slowed the development of chronic kidney disease and lowered the risk for cardiovascular events in patients with type 2 diabetes.
Bayer's CKD treatment gets FDA priority review status
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.